Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us

Menthol Not Proven to Raise Disease Risk, Draft Report Says

March 1 (Bloomberg) -- Smokers don’t face more risks of tobacco-related disease from menthol cigarettes than unflavored cigarettes, a U.S. advisory panel says in a preliminary report.

“The evidence is insufficient” to conclude that menthol smokers face a different disease risk than people who use regular cigarettes, said advisers to the Food and Drug Administration. Still, menthol may make smoking more addictive, the panelists said. The comments were posted yesterday on the FDA website in two draft chapters of a report the panel must submit by March 23.

The FDA advisers’ non-binding report is required by a 2009 law that restricts tobacco marketing and bars cigarette makers from adding flavors such as clove or strawberry. An FDA conclusion that menthol cigarettes are more dangerous than unflavored versions may lead to a ban.

Menthol products account for about 30 percent of the $85 billion in annual U.S. cigarette sales. Lorillard Inc.’s Newport is the top-selling menthol brand with $5 billion a year in revenue, followed by Marlboro Menthol from Altria Group Inc. and Reynolds American Inc.’s Camel Menthol, Kool and Salem, according to data compiled by Bloomberg.

Robert Bannon, a spokesman for Lorillard, and Reynolds spokesman David Howard declined to comment on the draft report chapters. Altria spokesman William Phelps wasn’t immediately available for comment.

Lorillard Shares Rise

Lorillard, based in Greensboro, North Carolina, gained $1.21, or 1.6 percent, to $77.98 at 4:15 p.m. in New York Stock Exchange composite trading. Reynolds, of Winston-Salem, North Carolina, lost 33 cents, or 1 percent, to $33.99. Shares of Richmond, Virginia-based Altria declined 25 cents, or 1 percent, to 25.12.

There isn’t enough evidence to conclude that menthol smokers inhale more smoke or are exposed to higher nicotine levels than non-menthol smokers, according to a draft chapter titled “Effects Of Menthol on the Disease Risks of Smoking.”

Still, it is “biologically plausible” that menthol flavoring makes cigarettes more addictive, the panel said in a separate draft chapter, titled “The Physiological Effects of Menthol Cigarettes.”

“Menthol provides an unmistakable sensory experience --the minty taste, cooling sensation and throat irritation or impact,” the panelists said. “The taste and odor are pleasurable for menthol cigarette smokers and may reinforce smoking behavior.”

Broader Effect

Disease risks also aren’t the only indicator of menthol cigarettes’ impact on public health, panel members said in a draft of the report’s first chapter.

“The availability of menthol cigarettes could have no significant effect on risk for disease outcomes, yet have a significant effect on increasing initiation or reducing the success of cessation,” the panel said in its draft. “The resultant increase in the prevalence of smoking would represent a negative public health impact.”

The FDA’s Tobacco Products Scientific Advisory Committee reviewed decades of published studies and FDA research, along with marketing data submitted by Altria’s Philip Morris USA unit, Reynolds American and Lorillard, the three biggest U.S. tobacco companies,

Advisory panel members are scheduled tomorrow to discuss the draft chapters at a meeting.

Lorillard and Reynolds have sued the FDA to block the agency from “receiving or relying on” the advisory panel’s recommendations. Three of the eight panel members have conflicts of interest, according to the complaint filed Feb. 25 in federal court in Washington.

The three panelists have served as paid witnesses in lawsuits against the tobacco industry and take money from drug companies that make smoking-cessation aids, Lorillard and Reynolds said in the complaint. Altria isn’t part of the suit.

To contact the reporter on this story: Molly Peterson in Washington at mpeterson9@bloomberg.net

To contact the editor responsible for this story: Adriel Bettelheim at abettelheim@bloomberg.net

Please upgrade your Browser

Your browser is out-of-date. Please download one of these excellent browsers:

Chrome, Firefox, Safari, Opera or Internet Explorer.